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**Abstract**

Clinical depression entails cognitive deficits often across a range of domains including impairments, not only of memory but also executive functioning, such as decision-making, sustained attention ('concentration') and working memory, although these deficits are frequently age-dependent and correlated with discrete brain pathology. I will review evidence of heterogeneous and homologous patterns of cognitive deficit across a number of human and animal studies focusing especially on decision-making and attention, measured in a variety of ways. In addition, it is evident that depression is also associated with distinctive cognitive or affective biases evident in different settings, such as a tendency to say "no" in tests of memory recognition, to over-respond to faces expressing negative emotion, to over-react to negative feedback and also to respond more quickly to sad rather than happy words. These phenomena indicate the importance in depression of a motivational interface with respect to cognitive function and vice versa. By comparison, preclinical models of depression have frequently been criticised for their emphasis on species-typical maladaptive responses to stress (as in chronic mild stress, learned helplessness and 'behavioural despair'), that are more predictive of the effects of drugs assumed to have anti-depressant effects than the symptoms of human depression themselves. Recently however, relevant aspects of behaviour such as affective bias and response to negative feedback have been employed successfully in rodents in a manner parallel to what is measured in human depressed patients, using for example tests of generalisation and probabilistic reversal learning. These new tests may complement the rich translational tests we already have available for assessing other aspects of cognition in humans and experimental animals and their neural correlates.
